Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expects Sustainable Revenue Growth, Plans New Capital Markets Strategy in 2020

  • Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations
  • Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors
  • Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed on a major U.S. exchange, according to CEO Chris Bunka in a strategic update to shareholders ( While its shares remain “dramatically undervalued” at the moment, Bunka said, the company boasts a successful 2019 during which it signed different partnerships and agreements for use of its innovative DehydraTECH™ drug delivery platform.

The revolutionary drug delivery platform accelerates human intestinal cell absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sugars or sweeteners, and other unhealthy practices. It is applicable to a wide variety of bioactive substances, including cannabis and nicotine. The innovative technology makes it possible to deliver bioactive substances via oral ingestion bypassing potentially unhealthy and unsafe practices. It has been shown to accelerate CBD absorption by 499 percent and achieve a CBD blood concentration 319 percent higher than traditional formulation.

The company developed its platform based on recognition of the fact that inhalation poses certain risks. Edible ingestion makes it possible to absorb a substance in a healthier and safer way. The platform has also been proven to deliver up to 10 times more of active ingredients in comparison to traditional edibles. DehydraTECH™ is the first platform of its kind that allows users to access the primary benefits of inhalation – speed and efficiency – while circumventing the risks of inhalation.

Lexaria Bioscience currently has 16 patents granted and more than 60 patent applications worldwide and is the only company to hold a patent for improved delivery of all cannabinoids and nicotine. According to Bunka, one of the company’s biggest achievements in 2019 was receiving the first ever patents to use DehydraTECH™ with cannabinoids for the treatment of Alzheimer’s, Parkinson’s, schizophrenia and heart disease, in Australia. Lexaria is working to gain fast-track patent status for the same health conditions in the U.S. this year, which will allow the company to achieve one of its goals for 2020 – developing relationships in the pharmaceutical industry, as well.

In 2019, the company also finalized a new contractual relationship with a GMP-certified, FDA registered production company to get enhanced DehydraTECH™ powders to market in the U.S. with current capacity of roughly 200,000 servings per day. According to Bunka, this can increase to 400,000 servings per day within the same facility. “Lexaria is experiencing strong demand from many companies requesting pre-processed DehydraTECH-enhanced bulk powders for their specific product lines and with this facility, we can meet that demand,” he said in a news release.

In 2020, the company expects to more than double its entire 2019 revenue from existing clients in the context of a projected sustainable revenue growth all throughout the year and beyond by leveraging a rich pipeline of prospective additional clients to be onboarded the following months, Bunka explained. “One of our existing U.S. clients is embarking on an aggressive growth strategy from their home state to several additional states within the next year. Another existing U.S. client is in the next 90 days launching their bottled beverage with CBD and DehydraTECH technology within, generating first-ever revenue for Lexaria during Q1,” Bunka continued.

This revenue increase will support the company’s own future growth plans. To increase its market visibility and ultimately expand its customer base, Lexaria Bioscience plans to dramatically alter its capital markets strategy this year to qualify for listing on a nationally recognized U.S. exchange. The company has already met with several Wall Street investment banking firms for this purpose. Listing on a major U.S. exchange would allow Lexaria Bioscience access to a significantly larger audience of investors and open a path to a growing number of more lucrative strategic opportunities, Bunka concluded.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Lexaria Bioscience Corp. (LXRP). Bookmark the permalink.

Comments are closed.